High prevalence of oxacillinases in clinical multidrug-resistant Acinetobacterbaumannii isolates from the Tshwane region, South Africa - an update

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Lowings, Michelle ^a   Ehlers, Marthie Magdaleen ^a,b   Dreyer, Andries William ^c   Kock, Marleen Magdalena ^a,b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

Acinetobacterbaumannii; Beta lactamases; M PCR; MLST; PFGE

Indexed keywords

AMIKACIN; AMOXICILLIN; AMPICILLIN; BACTERIAL ENZYME; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; OXACILLINASE; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GES GENE; GIM GENE; HUMAN; IMP GENE; INFANT; KPC GENE; MALE; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; MULTIPLEX POLYMERASE CHAIN REACTION; NDM GENE; NEWBORN; NONHUMAN; OXA 23 GENE; OXA 24 GENE; OXA 51 GENE; OXA 58 GENE; PULSED FIELD GEL ELECTROPHORESIS; SIM GENE; SOUTH AFRICA; SPM GENE; VEB GENE; VIM GENE; ACINETOBACTER INFECTIONS; ANTIBIOTIC RESISTANCE; BACTEREMIA; DRUG EFFECTS; GENETICS; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; MULTIPLEX POLYMERASE CHAIN REACTION; SOUTH AFRICA; YOUNG ADULT;

EID: 84947069447     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1246-8     Document Type: Article

References (53)

1. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, et al. Genetic basis of multidrug resistance in Acinetobacterbaumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother. 2008;52:3837-43.
2. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The population structure of Acinetobacter baumannii: Expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS ONE. 2010;5:1-17.
3. Gbaguidi-Haore H, Dumartin C, L'Hériteau F, Péfau M, Hocquet D, Rogues A, et al. Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. J Antimicrob Chemother. 2013;68:461-70.
4. Peleg AY, Seifert H, Paterson DL. Acinetobacterbaumannii: Emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538-82.
5. Kock MM, Bellomo AN, Storm N, Ehlers MM. Prevalence of carbapenem resistance genes in Acinetobacter baumannii isolated from clinical specimens obtained from an academic hospital in South Africa. South Afr J Epidemiol Infect. 2013;28:28-32.
6. Fournier P, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2006;2:0062-72.
7. Maragakis LL, Perl TM. Acinetobacterbaumannii: Epidemiology, antimicrobial resistance and treatment options. Clin Infect Dis. 2008;46:1254-63.
8. Chuang Y, Cheng C, Sheng W, Sun H, Wang J, Chen Y, et al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacterbaumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102-9.
9. Javed A, Zafar A, Ejaz H, Zubair M. Frequency and antimicrobial susceptibility of Acinetobacter species isolated from blood samples of paediatric patients. Pak J Med Sci. 2012;28:363-6.
10. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:233-8.
11. Cisneros JM, Rodríquez-Baño J. Nosocomial bacteremia due to Acinetobacterbaumannii: epidemiology, clinical features and treatment. Clin Microbiol and Infect. 2002;8:687-93.
12. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. TRENDS Microbiol. 2006;14:413-20.
13. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20:440-58.
14. Maamoun HAH. Molecular characteristics of extended-spectrum beta-lactamases among gram-negative isolates collected in Cairo University hospital. Comp Clin Pathol. 2013;22:733-9.
15. Sonnevend A, Ghazawi A, Al Munthari N, Pitout M, Hamadeh MB, Hashmey R, et al. Characteristics of epidemic and sporadic strains of Acinetobacter baumannii isolated in Abu Dhabi hospitals. J Med Microbiol. 2013;62:582-90.
16. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacterbaumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010;35:219-26.
17. OXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacterbaumannii isolates in Taiwan. Antimicrob Agents Chemother. 2010;54:4575-81.
18. Héritier C, Poirel L, Fournier P, Claverie J, Raoult D, Nordmann P. Characterization of the naturally occurring oxacillinase of Acinetobaterbaumannii. Antimicrob Agents Chemother. 2005;49:4174-9.
19. Evans BA, Amyes SGB. OXA β-lactamases. Clin Microbiol Rev. 2014;27:241-63.
20. Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:1589-93.
21. Agodi A, Voulgari E, Barchitta M, Quattrocchi A, Bellocchi P, Poulou A, et al. Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two sicilian hospitals. J Hosp Infect. 2014;208:1142-51.
22. Constantiniu S, Romaniuc A, Iancu LS, Filimon R, Taraşi I. Cultural and biochemical characteristics of Acinetobacter spp strains isolated from hospital units. Am J Prev Med. 2004;12:35-42.
23. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacterbaumannii. Antimicrob Agents Chemother. 2007;51:3471-84.
24. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother. 2009;63:55-9.
25. Lee SY, Shin JH, Park KH, Kim JH, Shin MG, Sug SP, et al. Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital. J Clin Microbiol. 2014;52:931-9.
26. Pournaras S, Poulou A, Dafopoulou K, Chabane YN, Kristo I, Makris D, et al. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacterbaumannii. Antimicrob Agents Chemother. 2014;58:828-32.
27. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the PmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011;55:3370-9.
28. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, et al. Emergence of colistin-resistant in extremely drug-resistant Acinetobacterbaumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis. 2013;208:1142-51.
29. Thermo Scientific, 2013: Simple, rapid isolation of DNA from tough-to-lyse fungi and bacteria. www.zymoresearch.com/downloads/dl/file/id/215/d6007d.pdf. 2013
30. Ribot EM, Fair MA, Gautom R, Cameron DN, Hunter SB, Swaminathan B, et al. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella and Shigella for PulseNet. Foodborne Pathog Dis. 2006;3:59-67.
31. Fillaux J, Dubouix A, Concil J, Laguerre J, Marty N. Retrospective analysis of multidrug-resistant Acinetobacter baumannii strains isolated during a 4-year period in a university hospital. Infect Control Hosp Epidemiol. 2006;27:647-53.
32. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by Pulsed-Field Gel Electrophoresis: Criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233-9.
33. Peirano G, van der Bij AK, Freeman JL, Poirel L, Nordmann P, Costello M, et al. Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother. 2014;58:3762-7.
34. Institut Pasteur: Acinetobacter baumannii MLST Database. Available: http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html Last full update: 23 October 2014 Accessed: January 2015
35. Perovic O, Fortuin-de Smidt M, Chetty V. Antimicrobial resistance surveillance from sentinel public hospitals, South Africa, 2013. Comm Dis Surveil Bull. 2014;12:30-58.
36. OXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol. 2006;44:2974-6.
37. OXA-51-type β-lactamase genes are ubiquitous and vary within a strain in Acinetobacter baumannii. Int J Antimicrob Agents. 2006;28:110-3.
38. OXA-51-like by multiplex PCR on its own is not reliable for the identification of Acinetobacter baumannii. Int J Med Microbiol. 2013;303:88-9.
39. Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents. 2013;41:11-9.
40. Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. Collected over 10 years in three continents. Antimicrob Agents Chemother. 2006;50:756-8.
41. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacterbaumannii infections. Lancet Infect Dis. 2008;8:751-62.
42. Fournier P, Richet H. The Epidemiology and control of Acinetobacterbaumannii in health care facilities. Clin Infect Dis. 2006;42:692-9.
43. Liakopoulos A, Miriagou V, Katsifas EA, Karagouni AD, Daikos GL, Tzouvelekis LS, et al. Identification of OXA-23-producing Acinetobacter baumannii in Greece, 2010 to 2011. Euro Surveil. 2012;17:1-3.
44. OXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16:35-40.
45. OXA-23 gene in imipenem-susceptible Acinetobacter baumannii. Mem Inst Oswaldo Cruz. 2011;106:505-6.
46. Nordmann P, Poirel L. Acinetobacter baumannii: basic and emerging mechanisms of resistance. Eur Infect Dis. 2008;2:94-7.
47. Safari M, Saidijam M, Bahador A, Jafari R, Alikhani MY. High prevalence of multidrug resistance and metallo-β-lactamase (MβL) producing Acinetobacter baumannii isolated from patients in ICU wards, Hamadan, Iran. J Res Health Sci. 2013;13:162-7.
48. Decousser JW, Jansen C, Nordmann P, Emirian A, Bonnin RA, Anais L, et al. Outbreak of NDM-1-producing Acinetobacter baumannii in France, January to May 2013. Euro Surveill. 2013;18:1-4.
49. NDM-1 in non-baumannii Acinetobacter spp. in China. J Antimicrob Chemother. 2012;67:2114-22.
50. Adams-Haduch JM, Onuoha EO, Bogdanovich T, Tian G, Marschall J, Urban CM, et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol. 2011;49:3849-54.
51. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351-3.
52. Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010;65:490-5.
53. Voets GM, Fluit AC, Scharringa J, Stuart JC, Leverstein-van Hall MA. A set of multiplex PCRs for genotypic detection of extended-spectrum β-lactamases, carbapenemases, plasmid-mediated AmpC β-lactamases and OXA β-lactamases. Int J Antimicrob Agents. 2011;37:356-9.